₹6.80
(Market cap
₹2,448 Cr
Revenue (TTM)
₹362 Cr
P/E Ratio
59
P/B Ratio
5.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹42 Cr
-
ROE
24 %
-
ROCE
25.2 %
-
Industry P/E
39.7
-
EV/EBITDA
28.4
-
Debt to Equity
0.7
-
Book Value
₹195.2
-
EPS
₹42
-
Face value
10
-
Shares outstanding
11,121,255
10 Years Aggregate
CFO
₹168.68 Cr
EBITDA
₹304.64 Cr
Net Profit
₹175.75 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Beta Drugs
| 42.1 | -1.3 | 52.6 | 16.4 | 33.3 | 45.8 | -- |
|
BSE Healthcare
| 18.8 | 2.8 | 8.7 | 17.1 | 23.1 | 14.8 | 12.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Beta Drugs
| -18.0 | 40.8 | 107.0 | 10.9 | 436.7 | 58.9 | -0.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Beta Drugs
|
2,201.0 | 2,447.8 | 362.4 | 42.4 | -- | 24 | 59 | 5.8 |
| 3,281.6 | 26,870.9 | 1,461.8 | 387.4 | 34.5 | 25.2 | 69.6 | 15.5 | |
| 813.5 | 16,000.2 | 7,784.0 | 688.5 | 10.6 | 14 | 23.1 | 2.7 | |
| 449.9 | 17,241.8 | 2,141.5 | 58.5 | 5.8 | 3.3 | 162.3 | 4.5 | |
| 836.7 | 20,739.4 | 5,632.3 | 662.4 | 17.2 | 14.3 | 31.3 | 4.2 | |
| 1,532.2 | 17,579.4 | 1,543.3 | -48.6 | 3.6 | -0.6 | -- | 3.0 | |
| 218.7 | 29,103.3 | 9,205.3 | -371.8 | 1.7 | -3.8 | -- | 3.6 | |
| 1,804.4 | 29,891.8 | 1,935.8 | 288.2 | 20.6 | 29.8 | 103.7 | 22.3 | |
| 403.4 | 16,284.0 | 3,600.2 | 221.0 | 9.7 | 5.6 | 73.7 | 3.4 | |
| 1,977.1 | 32,103.6 | 3,564.0 | 414.0 | 15.3 | 8.4 | 78.5 | 6.4 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Beta Drugs
--
-
Incorporated
2005
-
Chairman
Rahul Batra
-
Managing Director
Rahul Batra
-
Headquarters
Baddi, Himachal Pradesh
-
Website
Looking for more details about Beta Drugs Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Beta Drugs
What is the current share price of Beta Drugs Ltd Today?
The share price of Beta Drugs Ltd is ₹2,201.00 (NSE) as of 28-Aug-2026 IST. Beta Drugs Ltd has given a return of 33.29% in the last 3 years.
What is the current PB & PE ratio of Beta Drugs Ltd?
The P/E ratio of Beta Drugs Ltd is 59.01 times as on 28-Aug-2026, a 49 premium to its peers’ median range of 39.70 times.
The P/B ratio of Beta Drugs Ltd is 5.83 times as on 28-Aug-2026, a 57 premium to its peers’ median range of 3.72 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
45.35 |
9.76 |
2024 |
31.00 |
7.55 |
2023 |
19.62 |
4.90 |
2022 |
21.90 |
5.89 |
2021 |
9.84 |
1.68 |
What is the 52 Week High and Low of Beta Drugs Ltd?
The 52-week high and low of Beta Drugs Ltd are Rs 2,807.90 and Rs 990.10 as of 30-Aug-2026.
What is the market cap of Beta Drugs Ltd?
Beta Drugs Ltd has a market capitalisation of ₹ 2,448 Cr as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Beta Drugs Ltd?
Before investing in Beta Drugs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.